Medscape Pathology & Lab Medicine provides you with breaking medical news; reference on drugs, diseases, and procedures; and free CME.
Joined January 2010
- Tweets3.3K
- Following639
- Followers3.9K
- Likes74
SAVE THE DATE 🗓️
Join Dr. Nabil F. Saba & Dr. Jarushka Naidoo to explore clinical care insights on NTRK fusions across lung & thyroid cancer.
🗓️ Oct 29
⏰ 11:30am EST
🔗 mdsc.pe/4k9208O
#Oncology #NTRKFusions
From early molecular testing to targeted therapy sequencing, our expert panel breaks down how identifying NTRK fusions transforms care in pediatric oncology.
Watch the expert breakdown here ➡️ mdsc.pe/4xlHwgv
#MedEd #CME #PrecisionMedicine
NTRK fusions are game changers in pediatric oncology, serving as actionable drivers that guide precision treatment strategies.
Catch the replay ➡️ mdsc.pe/4xlHwgv
#MedEd #CME #OncologyCare
Identifying an NTRK fusion as an oncogenic driver can completely redefine clinical management and treatment pathways for pediatric patients with rare tumors.
Watch the full discussion ➡️ mdsc.pe/4xlHwgv
#MedEd #CME #PediatricOncology
Starting in 1 HOUR ➡️
Ready to elevate patient care in NTRK fusion-positive cancers? Tune in live to get practice-oriented insights from expert faculty.
⏰ 2:00pm ET
🔗 mdsc.pe/45jrbg8
#Oncology #PrecisionMedicine #MedscapeEducation
LIVE TOMORROW ➡️ Explore emerging data & practical considerations for initiating therapy in NTRK fusion-positive cancers with expert faculty. Bring your Qs!
📅 July 31st
⏰ 2:00pm ET
🔗 mdsc.pe/45jrbg8
#Oncology #PrecisionMedicine #MedscapeEducation
How do you navigate treatment sequencing for NTRK fusion-positive cancers? Join our expert panel for a 15-min LIVE event on precision medicine in real-world care.
📅 July 31st
⏰ 2:00pm ET
🔗 mdsc.pe/45jrbg8
#Oncology #MedscapeEducation
SAVE THE DATE 🗓️
Join Dr. Sébastien Perreault & Dr. Michela Casanova live for insights into translating NTRK fusion data into real-world care across CNS, sarcoma, & pediatric cancers.
📅 July 31st
⏰ 2:00pm ET
🔗 mdsc.pe/45jrbg8
#Oncology #PrecisionMedicine
Medscape Pathology retweeted
Correcting the title of this presentation: It is actually... Tackling Cases of cSCC. How do YOU perform in patient simulations? You can watch it already in progress...
#MedscapeLIVE: "Improving Outcomes in Locally Advanced #NSCLC: The Role of Immune Checkpoint Inhibitors" at #ASCO19 pscp.tv/w/b8RQBDFlUkV4cExxbl…
Medscape Pathology retweeted
#MedscapeLIVE: "Improving Outcomes in Locally Advanced #NSCLC: The Role of Immune Checkpoint Inhibitors" at #ASCO19 pscp.tv/w/b8RQBDFlUkV4cExxbl…
Medscape Pathology retweeted
Medscape Poll: Are you fairly compensated compared to physicians in other specialties? Read, decide, vote. wb.md/2oDfezJ
22%Yes
57%No
21%Unsure
190 votes • Final results Medscape Pathology retweeted
Medscape poll: This surgeon lied to protect a colleague. wb.md/2ldKAbb Would you? Read, decide, vote.
18%Yes
37%No
35%It depends
10%Unsure
419 votes • Final results Medscape Pathology retweeted
Medscape Poll: If you had a do over, would you choose your medical specialty again? Read, decide, vote. wb.md/2kKZJ2O
52%Yes
23%No
13%Depends on the day
12%Unsure
665 votes • Final results
Medscape Pathology retweeted
#SABCS16 Poll: Are you hopeful that immunotherapy will eventually be useful in #breastcancer?
76%Yes
8%No
16%Unsure
168 votes • Final results Medscape Pathology retweeted
#SABCS16 Poll: What will you use in the first-line treatment of ER+, HER2- metastatic disease in postmenopausal women?
23%Palbociclib/letrozole
29%Aromatase inhibitor
42%Tamoxifen
6%Other Option
214 votes • Final results Medscape Pathology retweeted
#ASH16 Poll: Have you used CAR T Cell therapy in patients yet?
9%Yes
72%No
18%No, but considering
116 votes • Final results Medscape Pathology retweeted
#ASH16 Poll: Do you see patients with sickle cell disease?
55%Yes
31%No
14%No, but maybe in future
308 votes • Final results